Boehringer Ingelheim and Lilly have teamed up with the International Diabetes Federation (IDF) to conduct a new survey analysing the ‘early conversations’ between patients and physicians.
The new diabetes survey, which is set to be the largest multinational survey ever conducted on the topic, will interview more than10,000 people with type-2 diabetes and 6,500 physicians in more than 26 countries.
The focus of the survey will be the early conversations held during diagnosis between patients and their physicians, with a view to discovering the impact these early interactions have on a patient’s wellbeing and other self-reported outcomes.
Anne Belton, IDF vice president, said the early stages of diagnosis for type 2 diabetes could be “challenging and emotional”, making the early conversations “essential” to ensuring better outcomes in the long-term. Early and comprehensive management of type 2 diabetes can lead to better outcomes and help patients enhance their own care, which can improve blood glucose control and increase a patient’s life satisfaction.
“This new survey will provide valuable insights into these important conversations,” explained Anne, outlining her hope that results would “aid the development of solutions” and help to “deliver valuable support early on in the treatment pathway”.
Boehringer Ingelheim and Lilly, who are working with the IDF in the survey, are responsible for producing the clinically-proven treatment Trajenta for type 2 diabetes and have collaborated for several years in diabetes research and development. This new survey will aid the companies’ development of future treatment options for patients, with the earliest results are expected to be published at the beginning of 2014.